Gland Pharma reported a strong performance in Q3FY26, with revenue from operations increasing by 22% YoY to ₹16,954 Mn. Net profit also saw substantial growth, increasing by 37% YoY to ₹2,797 Mn. The company launched nine new molecules in the US market and signed a new CMO contract, contributing to a positive outlook.
Financial Performance
Gland Pharma’s Q3FY26 results showcase significant growth:
- Revenue from operations: Increased by 22% YoY to ₹16,954 Mn (from ₹13,841 Mn).
- Total Income: Grew by 22% YoY to ₹17,585 Mn.
- Adjusted PAT: Increased by 37% YoY to ₹2,797 Mn (from ₹2,047 Mn).
Segmental Revenue
A geographical breakdown of revenue:
- US Market: Saw a 19% YoY increase.
- Europe Market: Experienced a 54% YoY increase.
- Other Core Markets: Reported a slight decrease of 1% YoY.
- Rest of World: Increased by 12% YoY.
Business Updates
Key business developments include:
- New Launches: Launched nine new molecules in the USA, including Argatroban, Acetazolamide, and Doxycycline.
- CMO Contract: Signed a contract for a Nano Drug Delivery System based injectable in Oncology.
- R&D Expenses: Increased to ₹650 million, representing 5.4% of revenue.
Cenexi Updates
- Revenue from Operations for Cenexi increased by 26%.
- Financial Performance saw increased volumes.
- New high-capacity ampoule line being added to Fontenay Facility.
Source: BSE
